MCF Advisors’s Outset Medical OM Stock Holding History

MCF Advisors’s Portfolio OM Stock Details OM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27	Closed	-$4.46K	–	971
2023 Q3	$4.46K	Sell	27 -12	-31%	-$2.83K	﹤0.01%	678
2023 Q2	$12.9K	Sell	39 -8	-17%	-$2.44K	﹤0.01%	534
2023 Q1	$12.9K	Buy	47 +6	+15%	+$2.2K	﹤0.01%	543
2022 Q4	$15.8K	Sell	41 -18	-31%	-$5.08K	﹤0.01%	476
2022 Q3	$14K	Buy	+59	New	+$15.8K	﹤0.01%	516

Other funds holding OM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

MCF Advisors's OM Position: Q4 2023 in Review

MCF Advisors sold out of Outset Medical (OM) in Q4 2023, closing a stake of 27 shares — an estimated $4.46K sold.

MCF Advisors first reported a position in OM in Q3 2022 and held it in 5 quarters. The position peaked at $15.8K in Q4 2022. 140 funds tracked by Wall St. Rank hold OM as of Q4 2023.

MCF Advisors reported no remaining Outset Medical position as of Q4 2023 after selling out during the quarter.
MCF Advisors sold 27 Outset Medical shares in Q4 2023, an estimated $4.46K.
MCF Advisors first reported a position in Outset Medical in Q3 2022 and held it in 5 quarters.
MCF Advisors's Outset Medical position peaked at $15.8K in Q4 2022.
140 funds tracked by Wall St. Rank held Outset Medical as of Q4 2023.

Based on MCF Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.